Replimune Group Inc
REPLHealthcare|Biotechnology|USA
$10.99
-0.12 (-1.08%)
Tangible Book
$2.01
Earnings Power
$1.15
Upcoming Data Readouts (11)
Oct 2026
Est. completion
P1Cancer
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
NCT04336241n=36
Nov 2026
Est. completion
P1Advanced Solid Tumor
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT04735978n=123
Jan 2027
Est. completion
P2High-Risk Oral Precancerous Disease
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
NCT06623110n=25
Dec 2027
Est. completion
P2Hepatocellular Carcinoma
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
NCT05733598n=60
Mar 2028
Est. completion
Early P1Melanoma
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
NCT06216938n=25
Jun 2028
Est. completion
P2Non-Small Cell Lung Cancer (NSCLC)
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348n=340
Jan 2029
Est. completion
P3Advanced Melanoma
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180n=400
Jul 2029
Est. completion
P1P2Merkel Cell Carcinoma
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
NCT04349436n=69
Oct 2029
Est. completion
P2Angiosarcoma
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
NCT06898970n=18
Jan 2030
Est. completion
P2P3Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406n=280
Dec 2030
Est. completion
Melanoma
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
NCT06887348n=50
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2025
P2
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436